Galenicum and Laboratorios Rubió sign a distribution agreement for Rubifen in Peru

February 26, 2013

Galenicum Health Peru and Laboratorios Rubió have signed an exclusive distribution agreement for Rubifen, to serve both private and institutional markets in the Andean country. The drug is used to treat attention deficit disorder with hyperactivity (ADHD) in adolescents and children aged 6 and older, in which other non-pharmaceutical measures alone have proved insufficient.